Citigroup’s Melinta Therapeutics, Inc. Common Stock MLNT Stock Holding History

Citigroup’s Portfolio MLNT Stock Details MLNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-783	Closed	-$3K	–	7896
2019 Q3	$3K	Sell	783 -363	-32%	-$1.31K	﹤0.01%	7507
2019 Q2	$8K	Sell	1,146 -1,082	-49%	-$4.12K	﹤0.01%	7378
2019 Q1	$8K	Sell	2,228 -38	-2%	-$206	﹤0.01%	7324
2018 Q4	$9K	Sell	2,266 -56	-2%	-$716	﹤0.01%	7220
2018 Q3	$46K	Buy	+2,322	New	+$58.7K	﹤0.01%	6599
2018 Q2	–	Sell	-1,017	Closed	-$38K	–	7822
2018 Q1	$38K	Buy	1,017 +589	+138%	+$38.7K	﹤0.01%	6375
2017 Q4	$33K	Buy	+428	New	+$31.7K	﹤0.01%	6458

Other funds holding MLNT

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

CCM

Condor Capital Management Martinsville, New Jersey $1.2B AUM 13.18% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

OAM

Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return

ARTA

A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return

Citigroup's MLNT Position: Q4 2019 in Review

Citigroup sold out of Melinta Therapeutics, Inc. Common Stock (MLNT) in Q4 2019, closing a stake of 783 shares — an estimated $3K sold.

Citigroup first reported a position in MLNT in Q4 2017 and held it in 7 quarters. The position peaked at $46K in Q3 2018. 37 funds tracked by Wall St. Rank hold MLNT as of Q4 2019.

Citigroup reported no remaining Melinta Therapeutics, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
Citigroup sold 783 Melinta Therapeutics, Inc. Common Stock shares in Q4 2019, an estimated $3K.
Citigroup first reported a position in Melinta Therapeutics, Inc. Common Stock in Q4 2017 and held it in 7 quarters.
Citigroup's Melinta Therapeutics, Inc. Common Stock position peaked at $46K in Q3 2018.
37 funds tracked by Wall St. Rank held Melinta Therapeutics, Inc. Common Stock as of Q4 2019.

Based on Citigroup's 13F filing for Q4 2019, filed 12 Feb 2020.